🟢 Indaptus Therapeutics is trading 5.65% up in after-hours trading after reporting a narrower second-quarter loss

Indaptus Therapeutics is trading 5.65% up at $1.12 in after-hours trading after its August 13, 2026, second-quarter earnings release and narrower loss.

• Net loss was $1.8 million, down from $5.2 million; EPS was a $0.02 loss, reportedly beating the $1.57 estimate.
• Management highlighted sharply lower expenses and $11.6 million in cash and short-term investments.
• The update pivoted toward neurological research and strategic alternatives after halting Decoy20 enrollment; volume details were unavailable.